Mucositis Research Group, Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, Level 4 East Wing, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia. dorothy.keefe@ health.sa.gov.au
Nat Rev Clin Oncol. 2011 Dec 20;9(2):98-109. doi: 10.1038/nrclinonc.2011.192.
The advent of targeted anticancer therapies over the past few decades has reinvigorated the field of cancer therapeutics, with the promise of increased cancer cure rates accompanied by decreased toxicity. But, has that promise been fulfilled? The short answer is definitely 'no', both because of disappointing tumor responses and unexpectedly high toxicity, as well as the extremely high financial cost of these agents. However, failing to completely fulfill initial promise does not mean that targeted therapies should be abandoned. Increased progression-free survival might ultimately lead to increased overall survival, and targeted therapies have changed the course of cancers such as breast, lung and renal. Therefore, we would argue that despite some disappointments, targeted therapies have a vital role in future cancer treatment. This Review will discuss the positives and negatives of targeted agents, and propose a way to optimize their use and development to ensure proper personalized cancer medicine that tailors not only the anticancer treatment, but also the antitoxicity strategies, to achieve the best outcome for the patient in terms of both quality and quantity of life.
在过去几十年中，靶向抗癌疗法的出现重新激发了癌症治疗领域的活力，有望提高癌症治愈率，同时降低毒性。但是，这个承诺实现了吗？简短的回答是“否”，这既是因为肿瘤反应令人失望，也是因为毒性意外升高，以及这些药物的极高财务成本。然而，未能完全实现最初的承诺并不意味着应该放弃靶向治疗。无进展生存期的延长最终可能导致总生存期的延长，并且靶向治疗已经改变了乳腺癌、肺癌和肾癌等癌症的治疗进程。因此，我们认为，尽管存在一些失望，但靶向治疗在未来癌症治疗中具有重要作用。本综述将讨论靶向药物的优缺点，并提出优化其使用和开发的方法，以确保适当的个性化癌症药物，不仅针对抗癌治疗，还针对抗毒性策略，从而在生活质量和数量方面为患者取得最佳结果。
